AIER Eye Hospital Group is China's leading ophthalmology hospital group that covers Asia, Europe, and North America with huge scale and outstanding medical capacity. It has three listed companies in China (stock code: 300015) , Europe (Spain: CBAV), and Southeast Asia (Singapore: 40T) with a total number of more than 600 specialized eye hospitals and centers and the annual outpatient visits in mainland China exceeded 10 million. Among those eye hospitals and centers, there are more than 500 in Mainland China, 7 in Hong Kong, 1 in the United States, more than 80 in Europe, and 12 in Southeast Asia. AIER is committed to the parallel introduction and absorption of world-leading ophthalmic technology and management concept, with professionalism, scale and science as its strategy to advance China's ophthalmic medical care. In the process of rapid development, AIER has gathered and cultivated a group of experienced and innovative management team and a team of ophthalmologists with excellent medical ability and rigorous academic background. As of April, 2020，AIER has more than 36,000 employees globally, including 7,400 ophthalmologists and optometrists. Ophthalmologists in AIER consist of a large number of Master's supervisor, PH.D supervisor, Ph.D, Post doctorates, scholars trained in Europe and the United States and core experts with rich clinical experience. They are a high-profile core force in the field of ophthalmology in China.
